Nektar Therapeutics

NASDAQ:NKTR

Biotechnology

Healthcare
$34.42 -2.04%

-$1.24 today

Market cap
$987.44M
Beta
1.15
P/E (TTM)
-9.3
EPS (TTM)
-$6.39
52W Low $8.27High $109.00

Volume 0.71M

Average 1.00M

NKTR Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Nektar TherapeuticsNASDAQ: NKTR

Other Income / Expenses · Q2 FY2026 · quarter ended Jun 2026

Other income / expenses turns positive

Q2 FY2026 other income / expenses was $2.04M, compared with -$5.55M a year earlier. Trailing-twelve-month other income / expenses was -$25.52M.

Context

  • Other income / expenses amounted to 60.6% of revenue in FY2025, up 46.3 pp from a year earlier.
  • Other income / expenses grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly other income / expenses holds near $2.04M or moves back toward the trailing-twelve-month quarterly average of -$6.38M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$2.04M+131.0% QoQ
Last fiscal yearDec 2025
-$33.44M-138.8% YoY
LTMJun 2026
-$25.52M-16.6% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+136.8%——
1 year-138.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
(33.44M) USD
Year-over-year change
-138.8%

Other Income / Expenses vs competitors

How NKTR compares with its peers on the latest reported figures

  • Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -16.6% is the 7th highest of 10, against a peer median of +6.3%.
  • Other income / expenses amounts to 46.8% of revenue for NKTR, versus a peer median of 7.1%.
NKTR Competitors
Other Income / Expenses for NKTR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
XNCRXencor, Inc.LTM Jun 2026$55.23M USD+206.4%+46.5%52.6%
RCUSArcus Biosciences, Inc.LTM Jun 2026$34M USD+6.3%+33.1%29.1%
IMCRImmunocore Holdings plcLTM Mar 2026$21.54M USD-13.2%+29.7%5.6%
ANLAdlai Nortye Ltd.LTM Jun 2024$11.25M USD—-72.8%173.3%
IPHAInnate Pharma S.A.FY2025€4.25M EUR+101.9%—152.4%
CGENCompugen Ltd.LTM Mar 2026$4.18M USD-19.6%+32.8%5.8%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$3.76M USD+136.9%——
IMTXImmatics N.V.LTM Mar 2026-€2.64M EUR-106.2%—7.1%
CHRSCoherus Oncology, Inc.LTM Mar 2026-$2.91M USD+59.5%—6.2%
MGNXMacroGenics, Inc.LTM Mar 2026-$7.37M USD-116.5%—4.7%
NKTRNektar TherapeuticsLTM Jun 2026-$25.52M USD-16.6%—46.8%
Peer median (excluding NKTR) —+6.3%+32.8%7.1%

Competitors are the stored peer set for NKTR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue101.91M92.06M90.12M98.43M55.23M
Cost of Revenue24.9M21.64M36.64M30.69M0
Gross Profit77.01M70.42M53.48M67.74M55.23M
Gross Margin75.6%76.5%59.3%68.8%100.0%
Research & Development400.27M218.32M114.16M120.91M117.33M
Selling, General & Admin122.84M92.33M77.42M76.75M68.67M
Operating Expenses523.11M310.66M190.9M172.94M186M
Depreciation & Amortization14.15M12.2M7.82M4.39M1.03M
EBITDA(461.82M)(323.87M)(243.11M)(86.7M)(137M)
EBITDA Margin-453.2%-351.8%-269.8%-88.1%-248.1%
Operating Income(446.1M)(240.24M)(137.43M)(105.2M)(130.77M)
Operating Margin-437.8%-261.0%-152.5%-106.9%-236.8%
Interest Income2.73M6.78M19.01M14.5M10.44M
Interest Expense47.31M28.91M25.33M28.11M26.18M
Other Income / Expenses(77.18M)(124.75M)(138.83M)(14M)(33.44M)
Income Before Tax(523.28M)(364.98M)(276.26M)(119.2M)(164.21M)
Pre-Tax Margin-513.5%-396.5%-306.5%-121.1%-297.3%
Income Tax Expense557K3.22M(200K)(239K)(138K)
Net Income(523.84M)(368.2M)(276.06M)(118.96M)(164.08M)
Net Margin-514.0%-400.0%-306.3%-120.9%-297.1%
EPS (Basic)(42.90)(29.51)(21.79)(8.68)(9.73)
EPS (Diluted)(42.90)(29.51)(21.79)(8.68)(9.73)
Weighted Avg Shares12.22M12.48M12.67M13.71M16.87M
Weighted Avg Shares (Diluted)12.22M12.48M12.67M13.71M16.87M

Nektar Therapeutics

NASDAQ:NKTR

Intrinsic Alpha fair value

Locked

Current Price

$34.42

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.